251 related articles for article (PubMed ID: 23102118)
21. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
22. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
Oh H; Madison C; Baker S; Rabinovici G; Jagust W
Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.
Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T;
Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127
[TBL] [Abstract][Full Text] [Related]
24. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
Shea YF; Ha J; Lee SC; Chu LW
Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
[TBL] [Abstract][Full Text] [Related]
25. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M
Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881
[TBL] [Abstract][Full Text] [Related]
26. Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load.
Alkalay A; Rabinovici GD; Zimmerman G; Agarwal N; Kaufer D; Miller BL; Jagust WJ; Soreq H
Curr Alzheimer Res; 2013 Jan; 10(1):48-56. PubMed ID: 23157337
[TBL] [Abstract][Full Text] [Related]
27. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
[TBL] [Abstract][Full Text] [Related]
28. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
Chhatwal JP; Schultz SA; McDade E; Schultz AP; Liu L; Hanseeuw BJ; Joseph-Mathurin N; Feldman R; Fitzpatrick CD; Sparks KP; Levin J; Berman SB; Renton AE; Esposito BT; Fernandez MV; Sung YJ; Lee JH; Klunk WE; Hofmann A; Noble JM; Graff-Radford N; Mori H; Salloway SM; Masters CL; Martins R; Karch CM; Xiong C; Cruchaga C; Perrin RJ; Gordon BA; Benzinger TLS; Fox NC; Schofield PR; Fagan AM; Goate AM; Morris JC; Bateman RJ; Johnson KA; Sperling RA;
Lancet Neurol; 2022 Feb; 21(2):140-152. PubMed ID: 35065037
[TBL] [Abstract][Full Text] [Related]
29. Relationships between biomarkers in aging and dementia.
Jagust WJ; Landau SM; Shaw LM; Trojanowski JQ; Koeppe RA; Reiman EM; Foster NL; Petersen RC; Weiner MW; Price JC; Mathis CA;
Neurology; 2009 Oct; 73(15):1193-9. PubMed ID: 19822868
[TBL] [Abstract][Full Text] [Related]
30. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species.
Oliveira F; Leuzy A; Castelhano J; Chiotis K; Hasselbalch SG; Rinne J; Mendonça A; Otto M; Lleó A; Santana I; Johansson J; Anderl-Straub S; Arnim C; Beer A; Blesa R; Fortea J; Sanna-Kaisa H; Portelius E; Pannee J; Zetterberg H; Blennow K; Moreira AP; Abrunhosa A; Nordberg A; Castelo-Branco M
Neuroimage Clin; 2018; 20():603-610. PubMed ID: 30186764
[TBL] [Abstract][Full Text] [Related]
31. Practical utility of amyloid and FDG-PET in an academic dementia center.
Sánchez-Juan P; Ghosh PM; Hagen J; Gesierich B; Henry M; Grinberg LT; O'Neil JP; Janabi M; Huang EJ; Trojanowski JQ; Vinters HV; Gorno-Tempini M; Seeley WW; Boxer AL; Rosen HJ; Kramer JH; Miller BL; Jagust WJ; Rabinovici GD
Neurology; 2014 Jan; 82(3):230-8. PubMed ID: 24353340
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging.
Yan Q; Nho K; Del-Aguila JL; Wang X; Risacher SL; Fan KH; Snitz BE; Aizenstein HJ; Mathis CA; Lopez OL; Demirci FY; Feingold E; Klunk WE; Saykin AJ; ; Cruchaga C; Kamboh MI
Mol Psychiatry; 2021 Jan; 26(1):309-321. PubMed ID: 30361487
[TBL] [Abstract][Full Text] [Related]
33. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
34. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
[TBL] [Abstract][Full Text] [Related]
35. Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study.
Mosconi L; Murray J; Davies M; Williams S; Pirraglia E; Spector N; Tsui WH; Li Y; Butler T; Osorio RS; Glodzik L; Vallabhajosula S; McHugh P; Marmar CR; de Leon MJ
BMJ Open; 2014 Jun; 4(6):e004850. PubMed ID: 24961717
[TBL] [Abstract][Full Text] [Related]
36. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
[TBL] [Abstract][Full Text] [Related]
38. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
39. MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
Banerjee G; Kim HJ; Fox Z; Jäger HR; Wilson D; Charidimou A; Na HK; Na DL; Seo SW; Werring DJ
Brain; 2017 Apr; 140(4):1107-1116. PubMed ID: 28335021
[TBL] [Abstract][Full Text] [Related]
40. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
Wang Y; Lou F; Li Y; Liu F; Wang Y; Cai L; Gordon ML; Zhang Y; Zhang N
Curr Alzheimer Res; 2021; 18(6):523-532. PubMed ID: 34598664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
